Form 6-K Cardiol Therapeutics For: Apr 28

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[   ] Form 20-F     [X] Form 40-F

 

 

SUBMITTED HEREWITH

Exhibits

Exhibit		Description
99.1		News Release dated April 28, 2026 - Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOL THERAPEUTICS INC.
	(Registrant)
Date: April 28, 2026	By:	/s/ Chris Waddick
		Chris Waddick
	Title:	Chief Financial Officer

 

 

ATTACHMENTS / EXHIBITS

NEWS RELEASE DATED APRIL 28, 2026

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• American Rebel Light Beer's NHRA Motorsports Platform Continues to Deliver High-Octane Results, Accelerating Brand Momentum and National Business Expansion
• Andrew Peller Ltd. Announces Timing of Q4 & Full-Year Fiscal 2026 Results & Conference Call
• ResumeTemplates.com Survey: Nearly Half of Hiring Managers Will Train AI Instead of Hiring 2026 College Grads